Gynecological disease
Conditions
Interventions
Oxaliplatin-combined with rimegepant group:Oxelizine 0.03mg/kg intravenously
Sufentanil composite etomidate group:Intravenous infusion of sufentanil 0.10 µg/kg
Sponsors
Qingdao Women and Children's Hospital (Peking University People's Hospital Qingdao Hospital)
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Scheduled hysteroscopic surgery; 2. Age 18-60 years; 3. American Anesthesiologists Association (ASA) classification I-II; 4. Body mass index (BMI) 18-28 kg/m².
Exclusion criteria
Exclusion criteria: 1. History of liver, kidney, or cardiovascular disease; 2. Severe hypertension (systolic blood pressure >=180mmHg or diastolic blood pressure >=110mmHg), diabetes (random blood glucose >=11.1mmol/l or fasting blood glucose >=7mmol/l); 3. Concomitant central nervous system disease; 4. Obstructive airway; 5. Allergy to the investigational drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| body movement; | — |
Secondary
| Measure | Time frame |
|---|---|
| Respiratory depression;Time to action of the two groups;hemodynamics;Total dose of etomidate;Recovery time of consciousness; | — |
Countries
China
Contacts
Public ContactHan Long
Qingdao Women and Children's Hospital (Peking University People's Hospital Qingdao Hospital)
Outcome results
None listed